Lipitor ad features consumer friendly risk information format

Share this article:
Pfizer this week debuted a new, consumer-friendly risk information presentation format in a DTC print ad appearing in The New York Times and The Wall Street Journal for its blockbuster cholesterol drug Lipitor.
"This is the first one out of the box," Pfizer spokeswoman Michal Fishman told MM&M. "We hope to have FDA approval for that format to be used in other print ads and also on the Web for our other medicines going forward."
The new Lipitor ad also features prominent presentation of risk information,promotes the drug as one of several treatment options including diet and exercise, and provides consumers with information on available assistance for paying for medications
through Pfizer's Helpful Answers program.
Pfizer said the ad is consistent with changes to DTC that it committed to in August to make its ads more effective at communicating risk and benefit information and reinforcing doctor/
patient relationships.
Fishman said the ad is not part of a new campaign but will "fill in" as Pfizer prepares to unveil a new Lipitor campaign later in the fourth quarter of 2005. The new consumer branded and unbranded campaign was announced in October.
Pfizer has yet to announce an agency selection for the account.
Three agencies--JWT, Mcgarrybowen and Kaplan Thaler Group-- are understood to be in the running.
The incumbent, Merkley + Partners, was eliminated in an earlier round, as was Hill Holliday.
Cholesterol-lowering Lipitor is the best-selling prescription drug in the world, with sales topping $11 billion last year.U.S. sales accounted for $7.7 billion. Major media spending on Lipitor has jumped over the past four years, from approximately $50 million in 2001 to about $120 million
in 2004, according to figures from Nielsen Monitor-Plus. Spending in the first four months of 2005 totaled $35 million. Estimated billings on Merkley's portion of the business are $60 million to $80 million.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...